Advertisement

Four Issues in Cost-Effectiveness Analysis and Health Technology Assessment: a View from the Touch-line

  • Anthony J. Culyer
Chapter
  • 952 Downloads

Abstract

Like many fathers and grandfathers, I have spent long hours in bad weather on touchlines urging on bunches of muddy little – and not so little – knots of boys and girls in amateur soccer league matches (in my case it has been almost exclusively soccer – a game I never played myself).

Keywords

Decision Maker Economic Evaluation Health Technology Assessment Societal Perspective Standard Gamble 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    http://htaglossary.net/HomePage, accessed 19 May 2014.
  2. 2.
    Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press. 1987.Google Scholar
  3. 3.
    Gold MR, Stevenson D, Fryback DG. HALYs and QALYs and DALYs, oh my: similarities and differences in summary measures of population health. Ann Rev Pub Health. 2002;23:115-34.Google Scholar
  4. 4.
    Culyer AJ, Lavers RJ, Williams AH. Social indicators: health. Soc Trends. 1971;2:31-42.Google Scholar
  5. 5.
    Luce BR, Drummond M, Jonsson B, Neumann PJ, Schwartz JS, Siebert U, Sullivan SD. EBM, HTA, and CER: Clearing the Confusion. Milbank Quarterly. 2010; 88:256-76.Google Scholar
  6. 6.
    Culyer AJ. The Dictionary of Health Economics. Cheltenham: Edward Elgar. 2014.Google Scholar
  7. 7.
    Wagstaff A, Pradhan M. Health insurance impacts on health and nonmedical consumption in a developing country. ICFAI J Risk and Ins. 2005;2:44-68.Google Scholar
  8. 8.
    van Doorslaer E, O’Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, Garg CC, et al. Effect of payments for health care on poverty estimates in 11 countries in Asia: an analysis of household survey data. Lancet. 2006;368:1357-64.Google Scholar
  9. 9.
    Smith DL, Levin SA, Laxminarayan R. Strategic interactions in multi-institutional epidemics of antibiotic resistance. Proc Nat Acad Sci of the USA. 2004;102:3153-8.Google Scholar
  10. 10.
    Megiddo I, Nandi A, Ashok A, Prabhakaran D, Laxminarayan R. IndiaSim: An Agent-based Model for Extended Cost-Effectiveness Analysis of Secondary Prevention of Coronary Heart Diseases in India, CDDEP working paper, Washington DC: CDDEP. 2014.Google Scholar
  11. 11.
    National Institute for Clinical Excellence. Supporting the Implementation of NICE Guidance, London: NICE. 2004.Google Scholar
  12. 12.
    Asaria M, Griffin S, Cookson R, Whyte S, Tappenden P. Distributional Cost-Effectiveness Analysis of Health Care Programmes, CHE Research Paper 91, York: Centre for Health Economics. 2013.Google Scholar
  13. 13.
    Verguet S, Laxminarayan R, Jamison DT. Universal public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis. Health Econ. 2014. doi:  10.1002/hec.3019. 2014.
  14. 14.
    Anand P. The integration of claims to health-care: a programming approach. J Health Econ. 2003;22:731-45.Google Scholar
  15. 15.
    Devlin NJ. Sussex J. (eds.) Incorporating Multiple Criteria in HTA: Methods and Processes. London: Office of Health Economics. 2011.Google Scholar
  16. 16.
    Morton A. Aversion to health inequalities in healthcare prioritisation: a multicriteria optimisation perspective. J Health Econ. (forthcoming 2014).Google Scholar
  17. 17.
    Culyer AJ, Lomas J. Deliberative processes and evidence-informed decision-making in health care – do they work and how might we know? Evidence and Policy. 2006;2:357-71.Google Scholar
  18. 18.
    Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235-51.Google Scholar
  19. 19.
    Bevan G, Hollingshurst S. Cost per quality adjusted life year and disability adjusted life years: the need for a new paradigm. Expert Rev Pharma and Outcomes Res. 2003;3:469-77.Google Scholar
  20. 20.
    Robberstad B. QALYs vs DALYs vs LYs gained: what are the differences, and what difference do they make for health care priority setting? Norsk Epid. 2005;15:193-91.Google Scholar
  21. 21.
    Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;12:429-45.Google Scholar
  22. 22.
    Williams A. Calculating the global burden of disease: time for a strategic reappraisal? Health Econ. 1999;8:1-8.Google Scholar
  23. 23.
    Murray CJL, Lopez AD. Progress and directions in refining the Global Burden of Disease approach: a response to Williams. Health Econ. 2000;9:69-82.Google Scholar
  24. 24.
    Klarman H, Francis J, Rosenthal G. Cost-effectiveness analysis applied to the treatment of chronic renal disease. Med Care. 1968;6:48-64.Google Scholar
  25. 25.
    Torrance GW. A Generalized Cost-Effectiveness Model for the Evaluation of Health Programs: A Research Report. Hamilton: McMaster University. 1970.Google Scholar
  26. 26.
    Zeckhauser R, Shepard DS. Where now for saving lives? Law and Contemp Probs. 1976;40:5-45.Google Scholar
  27. 27.
    Anand S, Hanson K. Disability-adjusted life years: a critical review. J Health Econ. 1997;16:685-702.Google Scholar
  28. 28.
    Sassi F. Calculating QALYs, comparing QALY and DALY calculation. Health Pol Plan. 2008;21:402-8.Google Scholar
  29. 29.
    Hausman D. Valuing health. Phil Pub Affairs. 2006;34:246-74.Google Scholar
  30. 30.
    Gold MR, Muennig P. Measure-dependent variation in burden of disease estimates: implications for policy. Med Care. 2002;40:260-6.Google Scholar
  31. 31.
    Johannesson M, Jönsson B, Jönsson L, Kobelt G, Zethreaus N. Why Should Economic Evaluations of Medical Technologies have a Societal Perspective? London: Office of Health Economics. 2009.Google Scholar
  32. 32.
    Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10:357-9.Google Scholar
  33. 33.
    Turvey R. Present value versus internal rate of return: an essay in the theory of third best. Econ J. 1963;73:93-8.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Anthony J. Culyer
    • 1
  1. 1.University of YorkYorkUK

Personalised recommendations